Sanofi Shares Plunge as Company Scraps 2025 Margin Target, Boosts R&D Spending
-
Sanofi shares plunge 15.5%, wiping $21 billion off market value, as it scraps 2025 profit margin target to increase drug development spending
-
CEO Hudson abandons 32% operating margin goal for 2025, now focuses on "long-term profitability"
-
Sanofi reviewing "potential separation scenarios" for consumer healthcare unit, most likely a capital markets transaction
-
2024 earnings forecast cut amid higher R&D spending, but strong rebound expected in 2025
-
Priority on immunology/inflammation, including Dupixent follow-ups, with aim to create "massive value" from late-stage trials